Vorolanib for advanced kidney cancer after first treatment
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a targeted therapy pill, vorolanib, for people with advanced kidney cancer that has clear cell features and has gotten worse after initial treatment. It may offer a new option when standard second-line treatments are not working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic kidney cancer with clear cell features that cannot be removed by surgery.
- You are between 18 and 80 years old and able to care for yourself (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans.
- You have not had any other cancer in the last 5 years, except for some easily curable types like certain skin or thyroid cancers.
- You have not had any other anti-cancer treatments (targeted therapy, immunotherapy, or experimental drugs) in the last 4 weeks.
- You do not have brain metastases, active autoimmune disease, or uncontrolled fluid buildup in the chest or belly.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment given before surgery for kidney cancer that is at high risk of coming back. The goal is to see if the treatment shrinks the tumor or improves surgery outcomes.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests a targeted therapy pill called Vorolanib for people with advanced non-small cell lung cancer who have already tried at least two other treatments. It aims to see if the drug can help shrink or control the cancer.
This trial tests a combination of two drugs, Vorolanib and Cadonilimab, for people with advanced or metastatic clear cell kidney cancer who have not had prior treatment. It aims to see if the combination shrinks the cancer and how safe it is.
This trial tests two drugs together—vorolanib (a pill that targets blood vessels in tumors) and sintilimab (an immunotherapy that helps your immune system fight cancer)—for people with advanced kidney cancer whose prior immunotherapy combination stopped working.
This trial tests a new combination of two oral drugs (vorolanib plus everolimus) versus the standard drug sunitinib in people with advanced clear cell kidney cancer that got worse after immunotherapy alone or with a targeted therapy. The goal is to see if the new combination works better.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.